Dihydromyricetin Ameliorates 3NP-induced Behavioral Deficits and Striatal Injury in Rats

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• Oxidative stress is a key factor in neurodegenerative diseases.
• 3-nitropropionic acid (3NP) is used to induce experimental models of neurodegeneration.

Purpose of the Study:

• To investigate the neuroprotective effects of dihydromyricetin (DHM) against 3NP-induced neurotoxicity.
• To evaluate DHM's impact on behavioral deficits and striatal histopathology.

Main Methods:

• Utilized behavioral tests, PET/CT imaging, biochemistry, histochemistry, and molecular biology techniques.
• Assessed motor function, learning, memory, glucose metabolism, oxidative stress markers (MDA, SOD), and apoptosis (Bcl-2, Bax, Cleaved Caspase-3).

Main Results:

• DHM treatment significantly improved motor function and cognitive impairments in 3NP-treated rats.
• DHM enhanced striatal glucose metabolism, reduced malondialdehyde (MDA), and increased superoxide dismutase (SOD) activity.
• DHM treatment markedly decreased striatal cell apoptosis and reversed alterations in apoptosis-related proteins (Bcl-2, Bax, Cleaved Caspase-3).

Conclusions:

• Dihydromyricetin (DHM) exhibits significant neuroprotective properties against 3-nitropropionic acid (3NP)-induced neurodegeneration.
• DHM exerts its protective effects via potent antioxidant and anti-apoptotic mechanisms, offering a potential therapeutic strategy for neurodegenerative conditions.